Endocrine Abstracts

Management of type-2 diabetes (T2D) should be individualised given recent increase in treatment options. There is a spectrum of phenotype of T2D from thinner patients who may be more insulin deficient to those who are overweight/obese and insulin resistant. We hypothesized that, if we are personalising treatment, thinner patients would be more likely to be treated with insulin secretagogues. To compare the management between these phenotypes, we reviewed 1007 patients with T2D...